Sino-C

Sino-C (0-20 μM, 48 h) exhibits broad-spectrum anticancer activity in CRC (HCT116, RKO, and MC38), lung cancer (A549 and NCI-H1299), and breast cancer (MDA-MB-231 and 4T1) cells^[1].
Sino-C (0-20 μM, 24 h) exhibits significant anti-CRC effect in HCT116 and RKO cells^[1].
Sino-C (0-20 μM, 24 h) induces HCT116 and RKO cell death, characterized by PARP cleavage without caspase-3 activation, causes severe morphological alterations (widened perinuclear spaces, extensive ER dilation with ribosome detachment, mitochondrial swelling) along with significant LDH leakage and membrane injury, suggesting a non-apoptotic mechanism^[1].
Sino-C (24 h) elicits a unique form of cell death: the morphological features do not match those of classical apoptosis, paraptosis, pyroptosis, or ferroptosis, but instead represent a hybrid mode combining both apoptotic and necrotic-like characteristics in HCT116 cells^[1].
Sino-C (0-20 μM, 24 h) upregulates cholesterol homeostasis-related genes, elevates intracellular cholesterol levels, and induces lipid droplet accumulation in HCT116 cells^[1].
Sino-C (0-20 μM, 24 h) induces cholesterol dysregulation, which leads to lipid peroxidation and subsequently triggers endoplasmic reticulum (ER) stress, ultimately contributing to CRC cell death^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.